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In 2014, a total of 2,976 Enterobacteriaceae isolates 
with decreased susceptibility to carbapenems were 
received at the French Associated National Reference 
Center for Antibiotic Resistance (NRC) and were char-
acterised for their molecular resistance mechanism 
to carbapenems and compared with results obtained 
during 2012 and 2013.The overall number of entero-
bacterial isolates with decreased susceptibility to 
carbapenems received at the NRC rapidly increased 
(more than twofold in two years) with a growing pro-
portion of carbapenemase producers (23.1% in 2012 vs 
28.6% in 2013 vs 36.2% in 2014). Between 2012 and 
2014, the main carbapenemase type was OXA-48, with 
an increase in OXA-48 variants (mostly OXA-181) and 
NDM producers, whereas the number KPC producers 
decreased. We identified a potential spread of OXA-
181 producers in the tropical region of Africa. Finally, 
OXA-48 and OXA-48-related enzymes remained the 
predominant carbapenemases in France. The number 
of carbapenemase-producing Escherischia coli iso-
lates was multiplied by fivefold between 2012 and 
2014, suggesting a possible dissemination in the 
community.
Introduction
During the last decade, Gram-negative isolates, in par-
ticular Enterobacteriaceae, with a decreased suscepti-
bility to carbapenems have been increasingly reported 
in Europe [1,2]. In Enterobacteriaceae, decreased sus-
ceptibility to carbapenems may be due to (i) a beta-
lactamase with significant hydrolytic activity towards 
carbapenems, i.e. a carbapenemase, or (ii) a combina-
tion of overexpression of beta-lactamases possessing 
a weak carbapenemase activity towards carbapen-
ems, i.e. extended spectrum beta-lactamase and/or 
cephalosporinase, with a decreased outer-membrane 
permeability or efflux overexpression [1]. The most 
clinically-relevant carbapenemases encountered in 
Enterobacteriaceae belong to either Ambler class A 
(mostly KPC-type) [3], or Ambler class B (metallo-beta-
lactamases (MBLs)) such as IMP-, VIM- and NDM-types) 
[1,4] or Ambler Class D (OXA-48-like enzymes) [5].
According to the results of the European Survey 
on Carbapenemase-producing Enterobacteriaceae 
(EUSCAPE) survey [6], four European countries (Greece, 
Italy, Malta, Turkey) are facing a situation where car-
bapenemase-producing Enterobacteriaceae (CPE) are 
endemic. However, endemicity is associated with dif-
ferent types of carbapenemases in different countries: 
in Greece VIM and KPC, in Italy KPC and in Malta and 
Turkey OXA-48. Although most European countries 
have reported an increase in the spread of CPE, once 
again, strong geographical differences exist in terms 
of the carbapenemase types involved. KPC produc-
ing Gram-negative bacteria were mostly reported in 
Italy and Greece. OXA-48 producers were more wide-
spread in some western European countries (Belgium, 
France, Spain) and in Romania and Turkey in the east-
ern part of the continent. VIM producers were endemic 
in Greece and interregional spread has been described 
in Italy, Spain and Hungary. Finally, NDM-producing 
Enterobacteriaceae were found to be more prevalent 
in central and eastern Europe (e.g. Poland, Romania). 
A precise identification of carbapenemase production 
and type is important for (i) the follow up of the spread 
of carbapenemase producers (ii) the timely identifi-
cation of outbreaks and their prevention and (iii) the 
choice of treatment with novel drugs such as ceftazi-
dime/avibactam active against producers of Ambler 
class A and D but not on class B carbapenemases [7].
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Figure 1
Geographic distribution of A. Isolates received at the French Associated National Reference Center for Antibiotic Resistance 
B. Carbapenemase-producing Enterobacteriaceae C. OXA-48-like-, NDM-, VIM-, KPC-, IMP- and IMI-producers, France, 
2012–2014
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Here, we assessed the epidemiology of 
Enterobacteriaceae with decreased susceptibility to 
carbapenems in France and analysed its evolution 
between 2012 and 2014.
Methods
Specimen collection
From January 2012 to December 2014, 6,682 enterobac-
terial isolates (1,485 in 2012; 2,225 in 2013 and 2,972 in 
2014) were received and tested for carbapenem activ-
ity at the French Associated National Reference Center 
for Antibiotic Resistance (NRC) in Le Kremlin-Bicêtre. 
Isolates were submitted from the whole of France, 
including French overseas territories. They were recov-
ered from both clinical and screening specimens, and 
sent on a voluntary basis by any type of laboratory 
(n = 486) related to any health facility such as private 
and public hospitals, nursing homes, and community 
laboratories (Figure 1A).
Isolates with reduced susceptibility to carbapenems 
(ertapenem, meropenem, or imipenem) according to 
the Antibiogram Committee of the French Society of 
Microbiology (CA-SFM) (i.e. inhibition diameter < 22 
mm, < 22 mm and < 25 mm for meropenem, imipenem 
or ertapenem respectively by disc diffusion) [8,9] were 
investigated for carbapenemase activity.
Figure 2
Distribution of carbapenemase-producing 
Enterobacteriaceae and non-carbapenemase-producing 
isolates by year, France, 2012–2014
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Figure 3
Distribution of OXA-48 variants among OXA-48-like 
carbapenemases by year, France, 2012–2014
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With each strain, provision of critical information was 
compulsory, such as the origin of specimens (screen-
ing rectal sample or any type of clinical sample), date 
of isolation, information regarding patient’s travel 
abroad in the year preceding the strain isolation (if yes, 
the country was recorded), the type of laboratory (hos-
pital, community laboratory).
Duplicated isolates from the same patient were 
excluded from the study. If different species or dif-
ferent carbapenemase types were recovered from the 
same patient, the corresponding isolates were taken 
into consideration individually. Isolates were also re-
identified at the NRC using a MALDI-TOF spectromet-
ric technique (Maldi-Biotyper, Bruker Daltonique SA, 
Wissembourg, France). Most of them were Klebsiella 
pneumoniae (36%), Enterobacter cloacae (33.3%) and 
Escherichia coli (15%).
Carbapenemase detection and molecular 
identification
The carbapenemase production was detected using 
the biochemical-based technique, the Carba NP test, 
as previously described [10]. Carbapenemase gene 
screening was performed by PCR aimed at identify-
ing the blaKPC, blaNDM, blaVIM, blaIMP, blaIMI and 
blaOXA-48-like genes [11]. In case of positive PCR, 
sequencing of the full-length gene was performed. A 
decreased susceptibility to carbapenems due to (i) an 
outer-membrane permeability defect, (ii) an overex-
pression of a cephalosporinase (chromosome-encoded 
or plasmid-acquired) associated with outer-membrane 
permeability defect, (iii) an extended spectrum beta-
lactamase (ESBL) production associated with outer-
membrane permeability defect or (iv) association of 
an ESBL and overexpression of a cephalosporinase 
outer-membrane permeability defect were suspected 
when the Carba NP test and PCR screening results were 
negative [12].
Results
Epidemiology of carbapenemase-producing 
Enterobacteriaceae
According to EUCAST breakpoints [13], most of the iso-
lates (99.6%, n = 6,655) received at the NRC were non-
susceptible to at least one of the three carbapenems 
tested (imipenem, meropenem, ertapenem). The num-
ber of enterobacterial isolates with decreased suscep-
tibility to carbapenems received at the NRC increased 
from 1,485 in 2012 to 2,225 in 2013 and 2,972 in 2014. 
The percentage of CPE among the Enterobacteriaceae 
with decreased susceptibility to carbapenems rose 
from 23.1% in 2012 to 28.6% in 2013 and 36.2% in 
2014 (Figure 2) [12].
In 2014, carbapenemases were OXA-48- (85.6%), NDM- 
(8.5%), VIM- (2.7%), KPC- (1.8%), and IMI-like enzymes 
(0.3%) (Table 1).
From 2012 to 2014, carbapenemase producers were 
recovered from patients hospitalised and/or living in 
three main regions: the north, the south-east and the 
Paris area (Figure 1B), mostly following the global geo-
graphic distribution of OXA-48-like producers (Figure 
1C). NDM producers seemed to be randomly scattered 
across France. Of note, all CPE, except one, recov-
ered on Réunion island, a French overseas depart-
ment and region in the Indian Ocean, were of the NDM 
type (Figure 1C). Finally, all CPE recovered in French 
New Caledonia were of the IMP type (Figure 1C). The 
number of OXA-48-like producers and NDM producers 
constantly increased from 2012 to 2014 (256, 512 and 
920 OXA-48-like producers and 27, 61 and 91 NDM pro-
ducers in 2012, 2013 and 2014, respectively). Contrary 
to this, the number of KPC producers decreased over 
the same period of time (39, 29 and 19 KPC produc-
ers in 2012, 2013 and 2014, respectively). One of the 
most relevant features observed between 2012 and 
2014 is the increased diversity of OXA-48-like produc-
ers, which is mostly related to the identification of the 
OXA-181 variant (Figure 3).
In addition, in 2014, an OXA-48-like variant with 
decreased susceptibility to carbapenems but devoid of 
any carbapenemase activity, OXA-405 was evidenced 
[14].
As previously observed, most of the carbapenemase-
producing Enterobacteriaceae obtained in 2014 were 
Figure 4
Known geographic origin of possible acquisition of 
infections and/or colonisations with carbapenemase-
producing Enterobacteriaceae, France, 2014 (n=140)
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Figure 5
A. Known geographic origin of possible acquisition of infections or colonisation with NDM- and VIM-producing 
Enterobacteriaceae (n=44) B. KPC-producing Enterobacteriaceae (n=4) C. OXA-48-like- producing Enterobacteriaceae 
(n=94), France, 2014
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C. Patients infected or colonised with OXA-48-like-producing Enterobacteriaceae 
Cross hatch box means
that the two carbapenemases 
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Cross hatch box means
that the two carbapenemases 
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nosocomially acquired bacterial species, including K. 
pneumoniae (57.1%), E. cloacae (9.9%) and Citrobacter 
freundii (3.5%) (Table 2 and Table 3) [12].
However, the number of carbapenemase-producers 
among carbapenem non susceptible E. coli isolates 
rose from 28.2 to 51.8% from 2012 to 2014. Of note, 46 
patients were colonised with multiple CPE isolates (rep-
resenting 106 isolates). In 93.5% (99/106) of the cases, 
the OXA-48 carbapenemase was identified reflecting 
the well-known de-repressed transfer properties of the 
incL/M OXA-48 prototype plasmid [15].
Mechanisms of decreased susceptibility to 
carbapenems in non-carbapenemase-producing 
Enterobacteriaceae
In the absence of carbapenemase production, the 
decreased susceptibility to carbapenems was mostly 
explained by a decreased outer-membrane permeability 
associated with the expression of an ESBL in K. pneu-
moniae (61.8%) and E. coli (50.4%). Overexpression of 
a chromosome-encoded cephalosporinase was mainly 
involved in natural producers of cephalosporinase 
that were Enterobacter spp. (61.6%), Citrobacter spp. 
(64.8%) and Serratia spp. (55.6%) (Table 3). Of note, 
for these non-carbapenemase producers, decreased 
susceptibility to ertapenem but retained susceptibility 
to imipenem and meropenem is frequently observed.
Colonisation vs infection with carbapenemase-
producing Enterobacteriaceae
Among the 1,075 CPE identified in 2014, 643 (59.8%) 
were from rectal swabs i.e. colonisation and 377 
(35.1%) from infection samples (Table 4). These two 
ratios remained the same since 2012 and were iden-
tical regardless of the carbapenemase type [12]. The 
most frequent clinical samples were urinary samples 
(68.2%) (Table 4).
Carbapenemase-producing Enterobacteriaceae 
colonisation and travel abroad
Although epidemiological data were sometimes not 
well documented, a possible importation from abroad 
was established for 13.2% (140/1,075) of patients colo-
nised or infected with a CPE in 2014, (27.6% (94/341) in 
2012 and 22.8% (145/636) in 2013 (Figure 4).
From 2012 to 2014, the identification of NDM-producing 
isolates was often linked to the Indian sub-continent 
(2012: 17/21; 2013: 17/30, 2014:23/42) where NDM-
producers are endemic [12]. In addition, identification 
of NDM-producers was also observed with travel asso-
ciation from North African (n = 13) and Middle Eastern 
countries (n = 3) (Figure 5A. KPC producers for which 
data were available (n=3) were mostly recovered from 
patients previously hospitalised in endemic countries 
for KPCs such as Greece (n = 1), Italy (n = 2) and the 
United States (US) (n = 1) (Figure 5B) [3]. Finally when 
a link with a foreign country was established (10.2% 
(n = 94) of the cases for OXA-48-like), OXA-48-like pro-
ducers were mostly recovered from patients with travel 
history to Africa and the Middle East (Figure 5C) cor-
responding to the known spread those CPE in these 
regions. The 52 OXA-48 variants, and mostly OXA-181 
variants (n = 29), were identified from patients return-
ing from the Indian subcontinent (n = 3), South-Eastern 
Asia (n  =  2), and from the tropical region of Africa 
(n = 5) (Figure 5C).
Discussion
Carbapenem-resistance in enterobacterial isolates 
from France were rising about twofold over a three 
year period with a growing impact of CPE among the 
Enterobacteriaceae with decreased susceptibility to 
Table 1
Distribution of carbapenemase types identified among 
carbapenemase-producing Enterobacteriaceae, France, 
2014 (n = 1,075)
Type of carbapenemase n %
OXA-48-like 920 85.6
KPC 19 1.8
NDM 91 8.5
VIM 29 2.7
IMP 3 0.3
IMI 3 0.3
OXA-48-like + NDM 7 0.7
OXA-48-like + VIM 2 0.2
NDM + VIM 1 0.1
Total 1,075 100
Table 2
Distribution of carbapenemase-producing 
Enterobacteriaceae by bacterial species, France 2014 
(n = 1,075)
Enterobacterial species n %
Klebsiella pneumoniae 614 57.1
K. oxytoca 19 1.8
Escherichia coli 256 23.8
Enterobacter cloacae 106 9.9
E. aerogenes 13 1.2
Other Enterobacter spp. 4 0.4
Citrobacter freundii 38 3.5
C. koseri 9 0.8
Other Citrobacter spp. 1 0.1
Serratia spp. 7 0.7
Proteus mirabilis 1 0.1
Other Proteae (Proteus spp.. Providentia spp.) 1 0.1
Morganella morganii 4 0.4
Other 2 0.2
Total 1,075 100
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carbapenems. The increased number of identified CPE 
mirrored the increasing number of reported nosoco-
mial outbreaks due to CPE in France [16]. However, the 
resistant isolates were sent by French laboratories to 
the NRC on a voluntary basis, making their exact prev-
alence rate unpredictable. For 80% of CPE episodes, 
sporadic cases or several cases related by an identi-
fied chain of transmission, documented by the French 
Public Health Agency, one or more isolates were char-
acterised by the NRC [17].
The analysis of the 6,682 strains with decreased sus-
ceptibility to carbapenems between 2012 and 2014 
highlights several features. The three main species 
with a decreased susceptibility to carbapenems were 
K. pneumoniae, Enterobacter spp. and E. coli. When 
compared to 2012, the number of CPE identified in E. 
coli was five times higher in 2014 [12]. This observa-
tion hints towards a possible future endemic spread of 
carbapenemase-producing E. coli in the community as 
previously observed for ESBL-producing E. coli.
Overall, the main carbapenemase type identified was 
OXA-48 as observed in several countries in west-
ern Europe (e.g. Belgium, France, Spain) [6]. We sug-
gest that the OXA-48 dissemination is likely the result 
of strong relationships and population movement 
between North African countries, where OXA-48 pro-
ducers are endemic, and France or Belgium and Spain 
[18-22]. A growing diversity of OXA-48-like variants 
was identified with OXA-181 most frequently reported. 
Although the occurrence of OXA-181 is known in the 
Indian subcontinent and South-Eastern Asia, colonisa-
tion with OXA-181 producers in the tropical region of 
Africa might be more important than expected.
The spread of OXA-181 producers might have previ-
ously been missed since one of the most widespread, 
for example in France, molecular commercial assay for 
the screening of CPE named Xpert Carba-R performed 
on the GeneXpert (Cepheid, Sunnyvale, CA, US), did 
not detect OXA-181 and OXA-232 variants until recently 
[23,24]. This failure was corrected in the 2015 version 
Table 3
Distribution of carbapenemase and non-carbapenemase-producing isolates by enterobacterial species, France, 2014
Enterobacterial 
species
Total 
number 
of 
isolates
Carbapenemase-producing Enterobacteriacease Non-carbapenemase-producing Enterobacteriacease
CPE
OXA-
48-
like
KPC NDM VIM IMP IMI OXA-48-like + NDM
OXA-48-
like + VIM NDM + VIM
Non 
CPE Case ESBL ESBL + Case Imper.
Susceptible to 
carbapenemsa
n n n n n n n n n n n n n n n n
Klebsiella spp. 1,180 633 552 17 51 9 1 0 3 0 0 547 68 338 24 113 4 
Escherichia 
coli 490 256 220 1 28 2 0 0 4 0 1 234 52 118 17 45 2 
Enterobacter 
spp. 1,073 123 101 1 6 9 1 3 0 2 0 950 585 18 326 21 0 
Citrobacter 
spp. 139 48 39 0 1 7 1 0 0 0 0 91 59 2 26 4 0 
Serratia spp. 25 7 5 0 0 2 0 0 0 0 0 18 10 2 0 5 1 
Other species 65 8 3 0 5 0 0 0 0 0 0 57 22 6 3 22 4 
Case: cephalosporinase; CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended spectrum beta-lactamase; Iperm: impermeability.
a Susceptible isolates after confirmation of minimum inhibitory concentration values [13].
Table 4
Distribution of specimens from which carbapenemase-producing Enterobacteriaceae were identified, France, 2014
Carbapenemase
Samples from which carbapenemase-producing Enterobacteriaceae were recovered:
TotalScreening 
samples 
(Colonisation)
Infections samples Information 
not 
availableUrine Blood
Respiratory 
tract Abscess Wound Other
Total 
infections
OXA-48-like 556 224 20 29 8 17 24 322 42 920
KPC 12 1 1 2 1 0 1 6 1 19
NDM 50 24 3 1 0 3 5 36 5 91
VIM 15 7 0 2 0 0 2 11 3 29
IMP 1 1 0 0 0 0 0 1 1 3
IMI 3 0 0 0 0 0 0 0 0 3
Multiple carbapenemases 6 0 1 0 0 0 0 1 3 10
Total 643 257 25 34 9 20 32 377 55 1,075
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of the test that is now available on the market [25,26]. 
This example underlines that CPE screening should 
not be limited to molecular tests. Several tests were 
recently developed for the detection of carbapenem 
hydrolysis activity such as (i) biochemical test (the 
Carba NP test and its derivatives RAPIDEC Carba NP, 
Rapid CARB Screen, blue Carba) [10,27,28], (ii) MALDI-
TOF based techniques [29], as well as electrochemical 
assays (the BYG test) [30]. In addition, in the context 
of such high prevalence of OXA-48 (ca  80% of the 
total CPE), rapid immunochromatographic tests able to 
detect all known OXA-48-like carbapenemases (OXA-
48 K-SeTs from Coris BioConcept, BioRad), might be of 
interest [31,32].
Although the origin of colonisation with a CPE producer 
was not always documented, it is likely that acquisition 
abroad is fuelling the growing number of CPE identified 
in France.
Taken together, our results may indicate that the 
spread of OXA-48 like and NDM-like producers may 
soon become difficult to control due to their silent 
spread in community-acquired E. coli as suggested as 
early as in 2012 [33,34]. Contrary to this, spread of KPC 
producers that were still identified mostly in K. pneu-
moniae, remained confined to nosocomial settings and 
should thus still be largely controllable. As exemplified 
in the public hospitals in Paris (AP-HP), a large regional 
multi-hospital institution, prevention of outbreaks due 
to CPE may remain possible when CPE is still mostly 
a nosocomial problem [16]. Based on our own experi-
ence and the results of this study, we advocate for a 
systematic screening of at-risk patients to identify car-
riers of CPE. Early screening of patients colonised with 
CPE is the pre-requisite for the rapid implementation 
of strict hygiene measures based on isolation of col-
onised patients and cohorting to prevent and control 
nosocomial outbreaks.
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